Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Status:
Completed
Trial end date:
2019-11-06
Target enrollment:
Participant gender:
Summary
This research study is being done to measure the clinical benefit of TRC105 in combination
with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients
who are taking either abiraterone or enzalutamide and showing signs of biochemical
progression without radiographic progression. A patient who is progressing on AR-therapy will
continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue
in parallel and independently.